Metraipolis › archive › dc_7c2591a14901
Preclinical Screening Platform Identifies Azatadine-Dimaleate as a Potent Repurposed Therapeutic Against SARS-CoV-2 Infection — Europe PMC PMID:41263140
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41263140
- DOI
- 10.1002/jmv.70713
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T21:12:48.079Z
- SHA-256 of the archived text
aeb68b8b43287833b295b803b66fdf1631e272ce343f880773e9a754b588895d- Stable URL of this page
https://metraipolis.com/documento/dc_7c2591a14901
How to cite
Preclinical Screening Platform Identifies Azatadine-Dimaleate as a Potent Repurposed Therapeutic Against SARS-CoV-2 Infection — Europe PMC PMID:41263140 — Europe PMC (en), https://europepmc.org/article/MED/41263140 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7c2591a14901 (Metraipolis archive dc_7c2591a14901, sha256 aeb68b8b43287833b295b803b66fdf1631e272ce343f880773e9a754b588895d)
BibTeX
@misc{dc7c2591a14901,
title = {Preclinical Screening Platform Identifies Azatadine-Dimaleate as a Potent Repurposed Therapeutic Against SARS-CoV-2 Infection — Europe PMC PMID:41263140},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41263140},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7c2591a14901; sha256 aeb68b8b43287833b295b803b66fdf1631e272ce343f880773e9a754b588895d},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41263140. Agents can read the archived copy with the MCP tool read_document.